Scarica l'app Stockscreener
20.36
1.04%
0.21
Dopo l'orario di chiusura:
20.36
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trend analysis for AnaptysBio Inc. this weekSwing Trade & Expert Curated Trade Setups - Newser
Fox Run Management L.L.C. Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. continue its uptrend2025 Buyback Activity & Consistent Profit Focused Trading Strategies - Newser
Can a trend reversal in AnaptysBio Inc. lead to recoveryJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Earnings visualization tools for AnaptysBio Inc.Market Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Historical volatility pattern of AnaptysBio Inc. visualizedJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
How to manage a losing position in AnaptysBio Inc.2025 Top Decliners & Community Consensus Trade Signals - Newser
How to read the order book for AnaptysBio Inc.Weekly Risk Report & Weekly Stock Performance Updates - Newser
Chart based exit strategy for AnaptysBio Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Will AnaptysBio Inc. stock go up soonBreakout Watch & Risk Controlled Swing Trade Alerts - Newser
Will breakout in AnaptysBio Inc. lead to full recoveryJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser
What does recent volatility data suggest for AnaptysBio Inc.Quarterly Portfolio Report & Real-Time Volume Analysis - Newser
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Investigational Rosnilimab Emerges as a Novel, Differentiated Treatment Option for Rheumatoid Arthritis - Fierce Biotech
Can machine learning forecast AnaptysBio Inc. recoveryJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
What makes AnaptysBio Inc. stock price move sharplyEarnings Trend Report & Weekly Breakout Opportunity Watchlist - mustnews.co.kr
UBS Group Reiterates Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Multi asset correlation models including AnaptysBio Inc.Layoff News & Long-Term Growth Stock Strategies - Newser
Is AnaptysBio Inc. a good stock for dollar cost averaging2025 Price Action Summary & Smart Allocation Stock Tips - sundaytimes.kr
Will AnaptysBio Inc. see short term momentumTrade Risk Summary & Consistent Return Strategy Ideas - Newser
How to recover losses in AnaptysBio Inc. stockPortfolio Return Report & Verified High Yield Trade Plans - Newser
Federated Hermes Inc. Lowers Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Inc. stock trend forecastTrade Volume Summary & Entry Point Strategy Guides - Newser
Wedbush Forecasts AnaptysBio's Q3 Earnings (NASDAQ:ANAB) - MarketBeat
Leerink Partnrs Forecasts Stronger Earnings for AnaptysBio - MarketBeat
Is AnaptysBio Inc. a defensive stock2025 Geopolitical Influence & Daily Profit Maximizing Trade Tips - kangso.co.kr
What technical models suggest about AnaptysBio Inc.’s comebackJuly 2025 Institutional & Momentum Based Trading Ideas - Newser
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at UBS Group - Defense World
AnaptysBio (NASDAQ:ANAB) Earns Neutral Rating from UBS Group - Defense World
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group - Defense World
AnaptysBio Inc. Matches Institutional Buying FilterMarket Trend Report & Weekly High Conviction Ideas - 선데이타임즈
UBS Maintains AnaptysBio(ANAB.US) With Hold Rating, Cuts Target Price to $20 - 富途牛牛
UBS Adjusts Price Target on AnaptysBio to $20 From $18, Maintains Neutral Rating - MarketScreener
What is Wedbush's Estimate for AnaptysBio Q4 Earnings? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 9.8%Should You Sell? - MarketBeat
UBS Raises AnaptysBio PT to $20, Maintains Neutral Rating - AInvest
Wedbush Raises AnaptysBio (NASDAQ:ANAB) Price Target to $45.00 - MarketBeat
AnaptysBio Receives Hold Rating from Truist Financial with $20 Target - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wedbush Weighs in on AnaptysBio’s Q3 Earnings (NASDAQ:ANAB) - Defense World
Federated Hermes Inc. Has $154,000 Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
What moving averages say about AnaptysBio Inc.Downside Control Plan With Support Analysis - Newser
AnaptysBio Reports Q2 2025 Financial Results and Updates - TipRanks
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $45.00 - Defense World
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
1.55%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):